Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 50 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2014', provides an overview of the Vaginal Atrophy (Atrophic Vaginitis)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Vaginal Atrophy (Atrophic Vaginitis) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Vaginal Atrophy (Atrophic Vaginitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vaginal Atrophy (Atrophic Vaginitis) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vaginal Atrophy (Atrophic Vaginitis) Overview 6
Therapeutics Development 7
Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Overview 7
Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Comparative Analysis 8
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics under Development by Companies 9
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Vaginal Atrophy (Atrophic Vaginitis) - Products under Development by Companies 13
Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development 14
Foamix Ltd. 14
Pantarhei Bioscience BV 15
Hygeia Therapeutics, Inc. 16
EndoCeutics, Inc. 17
TherapeuticsMD Inc. 18
Peptonic medical AB 19
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
prasterone - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
(estrogen + progesterone) - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
oxytocin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TX-12004HR - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
HYG-102 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
HYG-101 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
estradiol hemihydrate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Vaginal Atrophy (Atrophic Vaginitis) - Recent Pipeline Updates 41
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects 43
Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones 44
Featured News & Press Releases 44
Apr 07, 2014: TherapeuticsMD Reports Positive Results of Rabbit Irritation Study for Its Estradiol Vaginal Capsule VagiCap (TX 004-HR) for Treatment of Vulvar Vaginal Atrophy 44
Jan 28, 2014: TherapeuticsMD Reports Positive PK Study Results for Its Estradiol Vaginal Capsule VagiCap (TX 12-004-HR) for Treatment of Vulvar Vaginal Atrophy 44
Oct 22, 2013: TherapeuticsMD Phase 1 Pilot Study Shows TX-12-004-HR Estradiol VagiCap Improves Conditions of Vulvar and Vaginal Atrophy 45
Aug 12, 2013: TherapeuticsMD commences Phase I study of vulvar and vaginal atrophy candidate 46
Jun 14, 2013: TherapeuticsMD Announces FDA Accepts IND Application For TX12-004HR 47
Mar 27, 2013: Shionogi Announces EMA Acceptance Of Marketing Authorization Application For Ospemifene For Treatment Of VVA 47
Mar 01, 2013: Peptonic Medical Receives New Formulation Patent For Vagitocin In Sweden 47
Jan 05, 2012: Peptonic's Oxytocin Receives Approval For Dose-Finding Trial From Swedish Medical Products Agency 47
Nov 01, 2011: Peptonic Medical Announces Results From Clinical Proof Of Principle Study Of Oxytocin For Treatment Of vaginal atrophy 48
Apr 29, 2011: Peptonic Medical Signs Agreement With Recipharm For Production And Development Of Vagitocin For Clinical Study Program 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2014 7
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Foamix Ltd., H2 2014 14
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Pantarhei Bioscience BV, H2 2014 15
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Hygeia Therapeutics, Inc., H2 2014 16
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by EndoCeutics, Inc., H2 2014 17
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD Inc., H2 2014 18
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Peptonic medical AB, H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Assessment by Combination Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Recent Pipeline Updates, H2 2014 41
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H2 2014 43